Scarica l'app Stockscreener
1.82
0.00%
0.00
Dopo l'orario di chiusura:
1.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.82
Aprire:
$1.83
Volume 24 ore:
2.79M
Relative Volume:
0.51
Capitalizzazione di mercato:
$344.82M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.8585
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
-2.15%
1M Prestazione:
-13.33%
6M Prestazione:
+2.82%
1 anno Prestazione:
-30.27%
Intervallo 1D:
$1.78
$1.86
Intervallo di 1 settimana:
$1.78
$1.93
Portata 52W:
$1.58
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.82 | 344.82M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics executive sells shares worth $446 By Investing.com - Investing.com Australia
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Tuesday - MarketBeat
Esperion Therapeutics CFO sells shares for $20 - Investing.com India
Esperion Therapeutics executive sells shares worth $446 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat
Zacks Research Has Pessimistic Outlook of ESPR Q3 Earnings - MarketBeat
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - The Manila Times
Esperion Earnings Preview: Key Updates on 14,000-Patient CLEAR Trial & Next-Gen Cardiovascular Pipeline - StockTitan
Esperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at HC Wainwright - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Insider Alert: Esperion's Strategic Move58K RSUs Granted to Key New Hires - StockTitan
Esperion stock holds Buy rating, $16 target from H.C. Wainwright - MSN
Esperion stock target cut to $4 by JMP Securities - MSN
Esperion Therapeutics’ (ESPR) Market Outperform Rating Reaffirmed at JMP Securities - Defense World
Esperion stock holds Buy rating, $16 target from H.C. Wainwright By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ESPR Shares Experience Surge in Value - Knox Daily
SG Americas Securities LLC Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
What was Esperion Therapeutics Inc (ESPR)’s performance in the last session? - US Post News
Market Resilience: Esperion Therapeutics Inc (ESPR) Finishes Weak at 1.79, Down -1.10 - The Dwinnex
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
What is HC Wainwright's Estimate for ESPR FY2028 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for ESPR FY2028 Earnings? - Defense World
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright - Defense World
JMP Securities maintains $7 target on Esperion stock - MSN
JMP Securities maintains $7 target on Esperion stock By Investing.com - Investing.com Canada
Esperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Equities Analysts Set Expectations for ESPR FY2025 Earnings - MarketBeat
Cantor Fitzgerald Comments on ESPR FY2025 Earnings - Defense World
Esperion Therapeutics chief commercial officer sells $277 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells shares worth $20 By Investing.com - Investing.com South Africa
Esperion Therapeutics CFO sells shares worth $20 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLC - Defense World
Barclays PLC Grows Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion stock falls on higher operating expense forecast - MSN
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.92%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):